Corosan,Dipyridamole,cas:58-32-2 CAS NO.58-32-2
- FOB Price: USD: 120.00-140.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
98%(1-100)Kilogram98%(200-500)Kilogram
- Product Details
Keywords
- 58-32-2
- Dipyridamole
- Corosan
Quick Details
- ProName: Corosan,Dipyridamole,cas:58-32-2
- CasNo: 58-32-2
- Molecular Formula: C24H40N8O4
- Appearance: yellow powder
- Application: The drug is used in the treatment of H...
- DeliveryTime: Shipped in 15 days after payment
- PackAge: according to customers' requirements
- Port: China main port
- ProductionCapacity: 10000 Metric Ton/Month
- Purity: %
- Storage: ?20°C
- Transportation: Air, sea, land transport
- LimitNum: 1 Kilogram
Superiority
1. Dipyridamole has been shown to lower pulmonary hypertension without significant drop of systemic blood pressure
2. It inhibits formation of pro-inflammatory cytokines (MCP-1, MMP-9) in vitro and results in reduction of hsCRP in patients.
3. It inhibits proliferation of smooth muscle cells in vivo and has shown to prevent AV-shunt failure in dialysis patients.
4. It increases the release of t-PA from brain microvascular endothelial cells
5. It results in an increase of 13 - HODE and decrease of 12-HETE in the subendothelial matrix (SEM) and reduced thrombogenicity of the SEM.
Details
Product Name:dipyridamole
Formula:C24H40N8O4
Molecular Weight:504.72
CAS No.:58-32-2
EINECS:200-374-7
Density:1.352 g/cm3
Solubility:soluble in DMSO
Melting Point:165-166 °C(lit.)
Boiling Point:806.5 °C at 760 mmHg
Flash Point:441.5 °C
1.Dipyridamole is used to dilate blood vessels in people with peripheral arterial disease and coronary artery disease
2.Dipyridamole has been shown to lower pulmonary hypertension without significant drop of systemic blood pressure
3.It inhibits formation of pro-inflammatory cytokines (MCP-1, MMP-9) in vitro and results in reduction of hsCRP in patients.
4.It inhibits proliferation of smooth muscle cells in vivo and modestly increases unassisted patency of synthetic arteriovenous hemodialysis grafts.
5.It increases the release of t-PA from brain microvascular endothelial cells
6.It results in an increase of 13-HODE and decrease of 12-HETE in the subendothelial matrix (SEM) and reduced thrombogenicity of the SEM.
7.Pretreatment it reduced reperfusion injury in volunteers.
8.It has been shown to increase myocardial perfusion and left ventricular function in patients with ischemic cardiomyopathy.
9.It results in a reduction of the number of thrombin and PECAM-1 receptors on platelets in stroke patients.
10.cAMP impairs platelet aggregation and also causes arteriolar smooth muscle relaxation. Chronic therapy did not show significant drop of systemic blood pressure.
11.It inhibits the replication of mengovirus RNA.
12.It can be used for myocardial stress testing as an alternative to exercise-induced stress methods such as treadmills.icine.